natgillin/translations-raw huggingface dataset:
In the case of overdosage, symptomatic treatment should be initiated.
Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.
In the case of overdosage, symptomatic treatment should be initiated.
Pri prevelikem odmerjanju je treba uvesti simptomatsko zdravljenje.
In the case of overdose symptomatic treatment should be initiated.
Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.
In the case of overdose symptomatic treatment should be initiated.
Pri prevelikem odmerjanju uvedite simptomatsko zdravljenje.
In the case of overdose symptomatic treatment should be initiated.
Pri prevelikem odmerku je treba uvesti simptomatsko zdravljenje.
In the case of overdose symptomatic treatment should be initiated.
Pri prevelikem odmerku uvedemo simptomatsko zdravljenje.
In the case of overdose symptomatic treatment should be initiated.
V primeru prevelikega odmerka je potrebno uvesti simptomatsko zdravljenje.
In the case of overdose symptomatic treatment should be initiated.
V primeru prevelikega odmerka je potrebnu uvesti simptomatsko zdravljenje.
In the case of overdose, symptomatic treatment should be initiated.
Pri nenamernem vnosu prevelikega odmerka uvedemo simptomatsko zdravljenje.
In the case of overdose, symptomatic treatment should be initiated.
Pri prevelikem odmerjanju uvedemo simptomatsko zdravljenje.
In the case of overdose, symptomatic treatment should be initiated.
Pri prevelikem odmerjanju uvedite simptomatsko zdravljenje.
In the case of patients experiencing severe visual loss (best corrected visual acuity less than 6/60 in one or both eyes), XALKORI treatment should be discontinued and appropriate evaluation should be performed.
V primeru bolnikov, pri katerih se pojavi huda izguba vida (najboljša vidna ostrina s korekcijo manj kot 6/60 na enem ali obeh očesih), je treba z zdravljenjem z zdravilom XALKORI prenehati in izvesti primeren pregled.
In the case of persistence of uterine contractions during treatment with atosiban, alternative therapy should be considered.
Če se kontrakcije maternice med zdravljenjem z atosibanom nadaljujejo, je treba razmisliti o alternativni terapiji.
In the case of severe renal insufficiency, Dasselta should be used with caution (see section 5.2).
V primeru hude ledvične insuficience morate zdravilo Dasselta uporabljati previdno (glejte poglavje 5.2).
In the case of severe renal insufficiency, desloratadine should be used with caution (see section 5.2).
V primeru hude insuficience ledvic je treba desloratadin uporabljati previdno (glejte poglavje 5.2).
In the case of signs suggestive of an adrenal insufficiency, in addition to the general measures to eliminate the drug and reduce its absorption, a 100 mg dose of hydrocortisone should be administered at once, together with saline and glucose infusions.
Če znaki kažejo na adrenalno insuficienco, je treba poleg splošnih ukrepov za izločanje zdravila in zmanjšanje absorpcije takoj uporabiti tudi 100-miligramski odmerek hidrokortizona skupaj z infundiranjem fiziološke raztopine ter glukoze.
In the case of the following haemorrhagic events, the FVIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) within the corresponding period.
V primeru spodaj navedenih krvavitev aktivnost F VIII ne sme pasti pod navedeno raven aktivnosti v plazmi (v % normalne vrednosti ali i.e./dl) v ustreznem obdobju.
In the case of the following haemorrhagic events, the FVIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) within the corresponding period.
V primeru spodaj navedenih krvavitev aktivnost FVIII ne sme pasti pod navedeno raven aktivnosti v plazmi (v % normalne vrednosti ali i.e./dl) v ustreznem obdobju.
In the case of the haemorrhagic events listed, the factor VIII activity should not fall below the given level (in % of normal) in the corresponding period:
V primeru pojava navedenih krvavitev, aktivnost faktorja VIII v določenem obdobju ne sme pasti pod dano vrednost (% normalne vrednosti):
In the case of unvaccinated or incompletely vaccinated individuals, additional doses should be given as in the recommended immunisation schedule.
Necepljene ali nepopolno cepljene osebe morajo dobiti dodatne odmerke po priporočeni imunizacijski shemi.
In the case of unvaccinated or incompletely vaccinates individuals, additional doses should be given as in the recommended immunisation schedules.
Necepljene ali nepopolno cepljene osebe morajo dobiti dodatne odmerke po priporočeni imunizacijski shemi.
In the case the required concentration is 4 micrograms/ml:
V primeru, da je potrebna koncentracija 4 mikrograme/ml:
In the case the required concentration is 8 micrograms/ml:
V primeru, da je potrebna koncentracija 8 mikrogramov/ml:
In the cases evaluated close temporal relationship was reported coupled with a possible mode of action which supports a causal relationship between Ganfort and Dysgeusia.
V ocenjenih primerih so poročali o tesni časovni povezavi v kombinaciji z možnim načinom delovanja, kar podpira vzročno povezavo med zdravilom Ganfort in disgevzijo.
In the challenge studies performed by the company, insufficient protection was seen in approximately one quarter of horses vaccinated with the recommended dose.
V provokacijskih študijah, ki jih je opravila družba, je bila zaščita nezadostna pri približno eni četrtini konj, cepljenih s priporočenim odmerkom.
In the CINRGI trial, 186 term- and near-term neonates with hypoxic respiratory failure and without lung hypoplasia were randomised to receive either INOmax (n=97) or nitrogen gas (placebo; n=89) with an initial dose of 20 ppm weaning to 5 ppm in 4 to 24 hours with median duration of exposure of 44 hours.
V preskušanju CINRGI so naključno razdelili 186 novorojenčkov s hipoksično respiratorno odpovedjo in brez plučne hipoplazije, rojenih v roku ali blizu roka, tako da so prejemali bodisi zdravilo INOmax (n = 97) ali dušik v plinasti obliki (placebo; n = 89) v začetnem odmerku 20 ppm, ki so ga zmanjševali do 5 ppm v 4 do 24 urah z mediano trajanja izpostavitve 44 ur.
In the cirrhosis cohort, 4 patients with hepatocellular carcinoma underwent liver transplantation after 1–71 days of treatment; 3 of the
V kohorti s cirozo so 4 bolnikom s hepatocelularnim karcinomom po 1–71 dneh zdravljenja presadili jetra.
In the clinical programme patients aged 1 to < 3 years received 0.025 mg/kg zoledronic acid (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg zoledronic acid (up to a maximum single dose of 0.83 mg) every 3 months.
V kliničnem programu so bolniki v starosti od leta do < 3 leta prejeli 0,025 mg/kg zoledronske kisline (do največ 0,35 mg v enkratnem odmerku) vsake 3 mesece, bolniki v starosti od 3 do 17 let pa so prejeli 0,05 mg/kg zoledronske kisline (do največ 0,83 mg v enkratnem odmerku) vsake 3 mesece.
In the clinical studies conducted in infants, children and adolescents, the incidence and nature of symptoms after the first and second vaccination were similar to those occurred in adults or older people.
V kliničnih študijah pri dojenčkih, otrocih in mladostnikih sta bili pojavnost in narava simptomov po prvem in drugem cepljenju podobni kot pri odraslih in starostnikih.
In the clinical studies doses were reduced by 50 mg steps.
V kliničnih študijah so odmerke zmanjševali v korakih po 50 mg.
In the clinical studies in cancer patients, the most frequent strengths used were 100 and 200 micrograms.
V kliničnih raziskavah bolnikov z rakom sta bili najpogosteje uporabljeni jakosti 100 in 200 mikrogramov.
In the clinical studies mucosal bleedings (e.g. epistaxis, gastrointestinal, genitourinary) and anaemia were seen more frequently during long term edoxaban treatment compared with VKA treatment.
V kliničnih preskušanjih so med dolgotrajnim zdravljenjem z edoksabanom pogosteje opazili krvavitve iz sluznic (tj. iz nosu, prebavil, rodil in sečil) in slabokrvnost kot pri zdravljenju z VKA.
In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary) and anaemia were seen more frequently during long term rivaroxaban treatment on top of single or dual anti-platelet therapy.
V kliničnih preskušanjih so med dolgotrajnim zdravljenjem z rivaroksabanom poleg enotirnega ali dvotirnega antiagregacijskega zdravljenja pogosteje opazili krvavitve iz sluznic (tj. iz nosu, dlesni, prebavil, rodil in sečil) in slabokrvnost.
In the clinical studies of eltrombopag, overall no clinically significant differences in safety of eltrombopag were observed between subjects aged at least 65 years and younger subjects.
V kliničnih študijah, izvedenih z eltrombopagom, se varnost uporabe eltrombopaga pri bolnikih, starih vsaj 65 let, v celoti klinično ni pomembneje razlikovala od varnosti pri mlajših bolnikih.
In the clinical studies of Stribild over 144 weeks, 13 (1.9%) subjects in the Stribild group (n = 701) and 8 (2.3%) subjects in the ATV/r+FTC/TDF group (n = 355) discontinued study drug due to a renal adverse reaction.
V kliničnih študijah z zdravilom Stribild, ki so trajale 144 tednov, je 13 (1,9 %) oseb v skupini z zdravilom Stribild (n = 701) in 8 (2,3 %) osebi v skupini z ATV/r+FTC/TDF (n = 355) prenehalo sodelovati v študiji zdravila zaradi neželenega učinka na ledvice.
In the clinical studies only patients with cutaneous melanoma were studied.
V kliničnih študijah so preučevali le bolnike s kožnim melanomom.
In the clinical studies, Comfortis was compared with a veterinary medicine authorised in the EU for the treatment and prevention of flea infestations (selamectin, a ‘spot-on’ applied to the skin of the dog or cat).
V kliničnih študijah so zdravilo Comfortis primerjali z veterinarskim zdravilom, odobrenim v EU za zdravljenje in preprečevanje infestacije z bolhami (selamektin, zdravilo za kožni nanos za pse ali mačke).
In the clinical studies, most side effects were mild in nature and short term.
V kliničnih študijah je bila večina neželenih učinkov blagih in kratkotrajnih.
In the clinical studies, Onsior was compared with other veterinary medicines containing NSAIDs (ketoprofen, meloxicam or carprofen) or a placebo (dummy treatment).
V kliničnih študijah so zdravilo Onsior primerjali z drugimi veterinarskimi zdravili, ki so vsebovala nesteroidna protivnetna zdravila (ketoprofen, meloksikam ali karprofen) ali placebo (zdravilo brez zdravilne učinkovine).
In the clinical studies, patients randomised to simeprevir in combination with peginterferon alfa-2b and ribavirin obtained numerically lower SVR12 rates and also experienced viral breakthrough and viral relapse more frequently than those treated with simeprevir in combination with peginterferon alfa-2a and ribavirin (see section 5.1).
Bolniki, ki so bili v kliničnih študijah randomiziranih na simeprevir v kombinaciji s peginterferonom alfa-2b in ribavirinom so imeli številčno manjšo pogostnost doseganja SVR12, pogostejši virusni preboj in pogostejšo ponovitev bolezni v primerjavi z bolniki, ki so se zdravili s simeprevirjem v kombinaciji s peginterferonom alfa-2a in ribavirinom (glejte poglavje 5.1).
In the clinical studies, patients with serum creatinine > 400 μmol/l or > 4.5 mg/dl were excluded.
Bolnike s serumskim kreatininom > 400 µmol/l ali > 4,5 mg/dl so izključili iz kliničnih študij.
In the clinical studies, pre-dialysis patients were treated once-weekly with epoetin theta, 174 patients in the maintenance phase study and 111 patients in the long-term study.
V kliničnih študijah so bolnike, ki še niso na dializi, enkrat na teden zdravili z epoetinom theta – 174 bolnikov v študiji vzdrževalne faze in 111 bolnikov v dolgotrajni študiji.
In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10 % of the baseline value (see section 4.4).
V kliničnih študijah so nadaljevali z zdravljenjem z zoledronsko kislino šele, ko se je koncentracija kreatinina vrnila na raven, ne za več kot 10 % višjo od izhodiščne vrednosti (glejte poglavje 4.4).
In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4).
V kliničnih študijah so z zdravljenjem z zoledronsko kislino nadaljevali šele, ko se je vrednost kreatinina vrnila na raven, ki ne presega izhodiščne vrednosti za več kot 10% (glejte poglavje 4.4).
In the clinical study 38% of patients were ≥ 60 years of age and 12% of patients were ≥ 70 years of age.
V klinični študiji je bilo 38 % bolnikov starih  60 let, 12 % bolnikov pa je bilo starih  70 let.
In the clinical study conducted, the development of antibodies against the PEG moiety of peginterferon beta-1a had no discernible impact on safety, or clinical efficacy (including annualised relapse rate, MRI lesions, and disability progression).
V opravljenih kliničnih študijah ni imel razvoj protiteles proti delu PEG v peginterferonu beta-1a nikakršnega opaznega učinka na varnost ali klinični učinek (vključno z letno stopnjo recidiva, lezijami na MRS in napredovanjem bolezni).
In the clinical study evaluating ONIVYDE+5-FU/LV, 5 of 8 underweight patients experienced a grade 3 or 4 adverse reaction, mostly myelosuppression, while 7 of the 8 patients required dose modification such as dose delay, dose reduction or dose discontinuation (see section 4.4).
V klinični študiji, v kateri so vrednotili zdravilo ONIVYDE+5-FU/LV, je 5 od 8 bolnikov s premajhno telesno maso doživelo neželeni učinek 3. ali 4. stopnje, večinoma mielosupresijo, pri 7 od 8 bolnikov pa je bila potrebna sprememba odmerjanja, na primer odložitev odmerka, zmanjšanje odmerka ali prekinitev odmerjanja (glejte poglavje 4.4).
In the clinical study evaluating ONIVYDE+5-FU/LV, 5 of 8 underweight patients experienced a Grade 3 or 4 adverse reactions, mostly myelosuppression, while 7 of the 8 patients required dose modification such as dose delay, dose reduction or dose discontinuation.
V klinični študiji, v kateri so vrednotili zdravilo ONIVYDE+5-FU/LV, je 5 od 8 bolnikov s premajhno telesno maso doživelo neželeni učinek 3. ali 4. stopnje, večinoma mielosupresijo, medtem ko je bila pri 7 od 8 bolnikov potrebna sprememba odmerjanja, na primer odložitev odmerka, zmanjšanje odmerka ali prekinitev odmerjanja.
In the clinical study evaluating ONIVYDE+5-FU/LV, patients with a prior Whipple procedure had a higher risk of serious infections following treatment with ONIVYDE+5-FU/LV [9 of 29 (30%)] compared to 11 of 88 (12.5%) patients with no prior Whipple procedure.
V klinični študiji, v kateri so vrednotili zdravilo ONIVYDE+5-FU/LV, so imeli bolniki, ki so predhodno prestali Whipplovo operacijo, po zdravljenju z zdravilom ONIVYDE+5-FU/LV večje tveganje za resne okužbe [9 od 29 (30 %)] v primerjavi z 11 od 88 (12,5 %) bolnikov, ki niso prestali Whipplove operacije.
In the clinical study Grade 3 or Grade 4 diarrhoea occurred in 15 out of 117 patients (12.8%) receiving ONIVYDE+5-FU/LV.
V klinični študiji se je driska 3. ali 4. stopnje pojavila pri 15 od 117 bolnikov (12,8 %), ki so prejemali zdravilo ONIVYDE+5-FU/LV.
In the clinical study in men 16 to 26 years, 98.9%, 99.2%, 98.8%, and 97.4% of individuals who received Gardasil became anti-HPV
V klinični študiji pri moških, starih od 16 do 26 let, je med tistimi, ki so prejeli cepivo Gardasil, postalo v 1 mesecu po
In the clinical study in women 24 to 45 years, 98.4%, 98.1%,
V kliničnih študijah pri ženskah, starih od 24 do 45 let, je bilo 1 mesec po prejemu tretjega odmerka cepiva
In the clinical study in women 24 to 45 years, 98.4%, 98.1%, 98.8%, and 97.4% of individuals who received Gardasil became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3.
V kliničnih študijah pri ženskah, starih od 24 do 45 let, je bilo 1 mesec po prejemu tretjega odmerka cepiva Gardasil anti-HPV 6 seropozitivnih 98,4 % oseb, anti-HPV 11 seropozitivnih 98,1 % oseb, anti-HPV 16 seropozitivnih 98,8 % oseb in anti-HPV 18 seropozitivnih 97,4 % oseb.
In the clinical study programme the severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1 = mild, grade 2 = moderate, grade 3 = severe and grade 4=life-threatening.
V programu kliničnih študij so izraženost neželenih učinkov zdravila ocenjevali po dokumentu CTCAE, v katerem so stopnje izraženosti opredeljene takole: stopnja 1 = blaga, stopnja 2 = zmerna, stopnja 3 = huda in stopnja 4 = življenjsko nevarna.
In the clinical study, early diarrhoea onset occurred in 35 patients (29.9%) and cholinergic events occurred in 4 patients (3.4%) receiving ONIVYDE+5-FU/LV.
V klinični študiji se je zgodnja driska pojavila pri 35 bolnikih (29,9 %), holinergične reakcije pa pri 4 bolnikih (3,4 %), ki so prejemali zdravilo ONIVYDE+5-FU/LV.
In the clinical study, successful outcome was numerically slightly lower for C. tropicalis than for C. albicans at both dosages (100 and 150 mg daily).
V klinični študiji je bil uspešen izid številčno nekoliko manjši za C. tropicalis v primerjavi s C. albicans ob obeh odmerkih (100 in 150 mg na dan).
In the clinical trial (LUME-Lung 1; see section 5.1) with Vargatef, the frequency of bleeding in both treatment arms was comparable (see section 4.8).
V kliničnem preskušanju (LUME-Lung 1; glejte poglavje 5.1) zdravila Vargatef je bila pogostnost krvavitve pri obeh zdravljenih skupinah primerljiva (glejte poglavje 4.8).
In the clinical trial demonstrating effectiveness of ONIVYDE, higher plasma exposures of total irinotecan and SN-38 for patients in the ONIVYDE+5-FU/LV treatment arm were associated with longer OS and PFS as well as with higher ORR (objective response rate).
V kliničnem preskušanju za dokaz učinkovitosti zdravila ONIVYDE sta bili večja plazemska izpostavljenost skupnemu irinotekanu in SN-38 pri bolnikih v veji zdravljenja z zdravilom ONIVYDE+5-FU/LV povezani z daljšima OS in PFS ter višjim ORR (objektivno stopnjo odziva).
In the clinical trial in granulomatosis with polyangiitis and microscopic polyangitis, 99 patients were treated with MabThera (375 mg/m2, once weekly for 4 weeks) and glucocorticoids (see section 5.1).
V klinični študiji pri granulomatozi s poliangiitisom in mikroskopskem poliangiitisu so 99 bolnikov zdravili z zdravilom MabThera (375 mg/m2 enkrat na teden 4 tedne) in z glukokortikoidi (glejte poglavje 5.1).
In the clinical trial performed with IOA in the European Union the following Pearl Indices for the age class 18-35 years were calculated:
V kliničnem preskušanju, opravljenem z zdravilom IOA v Evropski uniji, so izračunali naslednje Pearlove indekse za starostno skupino 18 do 35 let:
In the clinical trial performed with IOA in the United States the following Pearl Indices for the age class 18-35 years were calculated:
V kliničnem preskušanju, opravljenem z zdravilom IOA v Združenih državah, so izračunali naslednje Pearlove indekse za starostno skupino 18 do 35 let:
In the clinical trial program, atypical femoral fractures were reported rarely in patients treated with denosumab (see section 4.4).
V programu kliničnih preskušanj so pri bolnikih, zdravljenih z denosumabom, redko poročali o atipičnih zlomih stegnenice (glejte poglavje 4.4).
In the clinical trial, the mean final dose of desoxycortone pivalate was 1.9 mg/kg (range 1.2–
V kliničnih preskušanjih je bil srednji končni odmerek dezoksikorton pivalata 1,9 mg/kg (razpon
In the clinical trials the outcome for anidulafungin with C. parapsilosis was not statistically different from other species however, the use of echinocandins in candidaemia due to C. parapsilosis may not be regarded as therapy of first choice
V kliničnih preskušanjih se izid za anidulafungin pri C. parapsilosis ni statistično razlikoval od drugih vrst, vendar pa uporaba ehinokamdine za zdravljenje kandidemije zaradi C.parapsilosis ne sme šteti kot zdravljenja prve izbire.
In the clinical trials, renal deterioration was defined as follows:
V kliničnih preskušanjih je bilo poslabšanje opredeljeno takole:
In the clinical trials, renal deterioration was defined as follows:
V kliničnih študijah je bilo ledvično poslabšanje opredeljeno, kot sledi:
In the clinical trials, there was an apparently higher incidence of infections among subjects ≥ 65 years of age, compared to younger subjects, although experience is limited.
V kliničnih študijah je bila pri bolnikih, starejših od 65 let, pogostost okužb v primerjavi z mlajšimi bolniki precej večja, čeprav so izkušnje omejene.
In the CLL11 study, 27% (90 out of 336) of patients treated with Gazyvaro plus chlorambucil had moderate renal impairment (CrCl < 50 mL/min).
V študiji KLL11 je imelo zmerno ledvično okvaro (očistek kreatinina < 50 ml/min) 27 % (90 od 336) bolnikov, zdravljenih s kombinacijo zdravila Gazyvaro in klorambucila.
In the cohort of patients not treated with a concomitant statin, the mean baseline LDL-C was 142.1 mg/dL.
V kohorti bolnikov, ki sočasno niso prejemali statina, je bil povprečni izhodiščni LDL-H 142,1 mg/dl.
In the cohort of patients on background statin, the mean baseline LDL-C was 112.7 mg/dL.
V kohorti bolnikov, ki so prejemali statin, je bil povprečni izhodiščni LDL-H 112,7 mg/dl.
In the cohort of post-MI or PAD patients with no history of stroke or TIA, the net clinical outcome analysis based on multiple occurrences of endpoints (CV Death/MI/Stroke/GUSTO Severe) is constant over time at each of the censoring times examined (12, 18, 24, 30, and 36 months) at cumulative 6-month intervals. (See Table 5.)
V skupini bolnikov po MI ali PAD brez anamneze možganske kapi ali TIA, je analiza neto kliničnih izidov na podlagi večkratnih pojavov končnih dogodkov (CV smrt/MI/možganska kap/GUSTO resni dogodki) konstantna v vsaki ocenjevani časovni točki (12, 18, 24, 30 in 36 mesecev) v 6-mesečnih intervalih. (Glejte preglednico 5.)
In the combination therapy arm of study MEK115306 pyrexia was reported in 57% (119/209) of patients with 7% Grade 3, as compared to the dabrafenib monotherapy arm with 33% (69/211) of patients reporting pyrexia, 2% Grade 3.
V študiji MEK115306 so v skupini bolnikov, ki so prejemali kombinirano zdravljenje, o zvišanju telesne temperature poročali pri 57 % (119/209) bolnikov, pri 7 % bolnikov je šlo za 3. stopnjo izraženosti, v primerjavi s skupino bolnikov, ki je prejemala dabrafenib v monoterapiji, pri kateri so o zvišanju telesne temperature poročali pri 33 % (69/211) bolnikov, pri čemer so o 3. stopnji izraženosti poročali pri 2 % bolnikov.
In the combined studies of GEMINI I and II the adverse reactions that occurred in ≥5% were nausea, nasopharyngitis, upper respiratory tract infection, arthralgia, pyrexia, fatigue, headache, cough.
Neželeni učinki, ki so se v kombinirani študiji GEMINI I in II pojavili pri 5 % bolnikov ali več, so bili navzea, nazofaringitis, okužba zgornjih dihal, bolečina v sklepih, zvišana telesna temperatura, utrujenost, glavobol in kašelj.
In the comparative study, Fasturtec was more effective than allopurinol: over the first 96 hours after treatment, patients treated with Fasturtec had a lower average blood level of uric acid than the patients treated with allopurinol (128.1 and 328.5 mg.h/dl, respectively).
V primerjalni študiji je bilo zdravilo Fasturtec učinkovitejše od alopurinola: v prvih 96 urah po zdravljenju so bolniki, ki so se zdravili z zdravilom Fasturtec, imeli nižje povprečne koncentracije sečne kisline v krvi kot bolniki, ki so se zdravili z alopurinolom (128,1 oziroma
In the comparator arm patients received 1% hydrocortisone acetate ointment (HA) for head and neck and 0.1% hydrocortisone butyrate ointment for trunk and limbs (n=111) twice a day for 2 weeks and subsequently HA twice a day to all affected areas.
V primerjalni skupini pa so bolniki prejeli mazilo z 1-% hidrokortizon acetatom (HA) za uporabo na predelu glave in vratu, ter mazilo z 0,1-% hidrokortizon butiratom za uporabo na predelu trupa in okončin (n=111), in sicer dvakrat dnevno v obdobju dveh tednov, v nadaljevanju pa HA, nanešeno dvakrat dnevno na vse prizadete predele telesa.
In the completed phase II and phase III registration studies, 4,006 patients were exposed to dulaglutide alone or in combination with other glucose lowering medicinal products.
V zaključenih registracijskih študijah 2. in 3. faze je bilo 4006 bolnikov izpostavljenih dulaglutidu samemu ali pa v kombinaciji z drugimi zdravili za znižanje glukoze.